Choroidal neovascularisation – Diagnostics – Overview of Information and Clinical Research

Choroidal neovascularisation is a serious eye condition where abnormal blood vessels grow beneath the retina, leaking fluid and blood that can damage vision. Early detection through eye exams and advanced imaging can help preserve sight, and understanding the diagnostic process is crucial for anyone at risk of this potentially vision-threatening complication.

Who Should Undergo Diagnostic Testing

Anyone experiencing sudden changes in their vision should seek immediate medical attention. If you notice that straight lines appear wavy or bent, or if you develop a dark or empty spot in the center of your vision, these could be early warning signs of choroidal neovascularisation. The condition often develops without pain, which means many people delay seeking help until significant damage has already occurred.

People with certain risk factors should be especially vigilant about regular eye examinations. Those with age-related macular degeneration, particularly the dry form, are at elevated risk of developing choroidal neovascularisation, which represents progression to the wet form of the disease. Individuals with extreme nearsightedness, known as high myopia, face increased vulnerability because the stretching and thinning of eye layers can trigger abnormal vessel growth. Additionally, people with a history of inflammatory eye conditions, eye trauma, or certain infections affecting the eye should maintain regular monitoring.^[1]^[2]

The urgency of diagnostic evaluation cannot be overstated. When abnormal blood vessels begin leaking fluid into the retina, time becomes a critical factor. The leaked fluid creates a “blister” effect in the normally flat retina, immediately distorting vision. Over days to months, this fluid damages and kills photoreceptors, the light-sensing cells essential for vision. An ophthalmologist can halt this damage by administering treatment, but only if the intervention occurs within hours or days of symptom onset. As the saying goes in eye care, time lost is vision lost.^[1]

⚠️ Important

Symptoms of choroidal neovascularisation include distorted or wavy central vision, a gray, black, or void spot in central vision, loss of vision without pain, difficulty seeing colors or recognizing faces, and apparent changes in image size. If you experience any of these symptoms, contact an ophthalmologist immediately for an emergency visit. Early detection and rapid treatment are essential to prevent permanent vision loss.

Older adults, particularly those over 60, should schedule comprehensive eye examinations even without noticeable symptoms. Choroidal neovascularisation can sometimes be detected in its early stages before dramatic vision changes occur. Modern imaging technology allows doctors to identify non-exudative neovascular membranes that are typically asymptomatic, meaning they haven’t yet caused noticeable vision problems but may progress.^[2]

Family history also plays a role in determining who should seek diagnostic testing. If close relatives have experienced age-related macular degeneration or choroidal neovascularisation, your risk increases. Lifestyle factors such as smoking significantly elevate risk as well. Research has shown that smokers have three times the risk of developing choroidal neovascularisation compared to non-smokers, with risk increasing with age.^[7]

Standard Diagnostic Methods

The diagnostic process for choroidal neovascularisation begins with a comprehensive dilated eye examination. During this examination, an ophthalmologist uses special drops to widen your pupils, allowing a clear view of the back of your eye. Through this dilated pupil, the doctor can often see visible signs of the condition, such as a blister of fluid in the retina or bleeding beneath it. This initial examination provides important clues, but confirming the diagnosis requires more sophisticated imaging techniques.^[1]

Optical Coherence Tomography

Optical coherence tomography, commonly called OCT, has become the imaging method of choice for diagnosing and managing choroidal neovascularisation. This painless test uses light waves to capture detailed, three-dimensional cross-sectional images of the retina, much like an ultrasound uses sound waves. The technology allows doctors to see the individual layers of the retina and identify abnormalities such as fluid accumulation, bleeding, or the presence of abnormal blood vessels.

What makes OCT particularly valuable is that it does not require any injections. You simply sit in front of the machine while it scans your eye. The resulting images show the retina’s structure in remarkable detail, revealing even subtle changes that might not be visible during a standard eye exam. Doctors can measure the exact thickness of the retina and track how fluid levels change over time, which helps them assess whether treatment is working.^[2]^[4]

Fluorescein Angiography

Fluorescein angiography was once considered essential for diagnosing choroidal neovascularisation, though its role has evolved with the advent of OCT. In this test, a special dye called fluorescein is injected into a vein in your arm. The dye travels through your bloodstream and reaches the blood vessels in your eyes. As it circulates, a special camera takes rapid photographs that show how the dye moves through the blood vessels in the retina and choroid.

The test reveals patterns that help doctors classify the type of choroidal neovascularisation. Classic CNV appears as a well-defined area that lights up brightly in early images and leaks in later images, obscuring its borders. Occult CNV has borders that cannot be clearly determined by the imaging. The test may also reveal fibrovascular pigment epithelial detachment, where the retinal pigment epithelium lifts away from the underlying tissue, or late leakage of undetermined source. These classifications help guide treatment decisions.^[2]

Fluorescein angiography also helps doctors determine the location of the abnormal vessels relative to the center of the macula. The neovascularisation may be classified as extrafoveal (far from the center), juxtafoveal (near the center), or subfoveal (directly under the center). Location matters because it affects both the visual impact and treatment approach.^[2]

Indocyanine Green Angiography

Indocyanine green angiography, or ICG, provides complementary information to fluorescein angiography. This test uses a different dye that absorbs and fluoresces in the near-infrared range of light. The advantage of this wavelength is that it can penetrate through blood, fluid, and pigment that would normally block visualization during standard fluorescein angiography. This makes ICG particularly useful when there is bleeding or thick fluid present.

Because indocyanine green binds tightly to proteins in the blood, less dye escapes from the blood vessels. This characteristic allows better visualization of the blood vessels in the choroid layer itself. Doctors look for specific patterns: a “hot spot” appears as a well-defined bright area smaller than the optic disc; a “plaque” shows as a larger bright area that doesn’t light up early; or combinations of both patterns may appear. These patterns help identify the source and extent of abnormal vessel growth.^[2]

Physical Examination Findings

Beyond imaging tests, the physical examination reveals important signs. When an ophthalmologist examines the back of your eye, they may observe blood beneath the retina, fluid accumulation, deposits of lipids (fatty substances), detachment of the retinal pigment epithelium, or scar tissue formation. In advanced cases, a disciform scar may develop, which is a fibrous scar that replaces normal retinal tissue and causes permanent vision loss. Recognizing these physical findings helps doctors understand the stage and severity of the condition.^[2]^[7]

Laboratory studies are typically not needed to diagnose choroidal neovascularisation itself. However, if doctors suspect an underlying condition such as pseudoxanthoma elasticum, a rare genetic disorder that affects connective tissue and can lead to choroidal neovascularisation, they may order specific blood tests or genetic studies to confirm the diagnosis.^[2]

Diagnostic Criteria for Clinical Trial Enrollment

Clinical trials investigating treatments for choroidal neovascularisation use standardized diagnostic criteria to ensure that participants truly have the condition and meet specific requirements. These criteria are more rigorous than those used in routine clinical care because research demands precise definitions and measurements.

Participants in clinical trials typically must demonstrate choroidal neovascularisation confirmed by multiple imaging methods. Optical coherence tomography serves as the primary tool, showing characteristic features such as subretinal or sub-retinal pigment epithelium fluid, abnormal vessel growth, or retinal thickening. Fluorescein angiography may be required to confirm active leakage from the abnormal vessels and to classify the type of neovascularisation.^[2]

Visual acuity requirements vary by study but are carefully specified. Some trials enroll patients only within a certain range of vision loss, measured using standardized eye charts. For example, a study might require that participants have a visual acuity between 20/40 and 20/320, meaning they can see at 20 feet what a person with normal vision can see at 40 to 320 feet. This ensures the study population is comparable and that potential treatment effects can be measured meaningfully.

The size and location of the choroidal neovascular lesion often matter for trial eligibility. Researchers may measure the total area of the lesion and specify that it must involve the center of the macula (subfoveal) or be positioned a certain distance from it. These anatomical specifications help ensure that the trial tests treatments in situations where they are most likely to be relevant.

Clinical trials frequently require documentation of disease activity. This might include evidence of recent vision changes, fresh bleeding, or increasing fluid on OCT scans. Some trials specifically recruit treatment-naive patients who have never received therapy for their choroidal neovascularisation, while others study patients who have previously been treated. The history of prior treatment, including which drugs were used and how the patient responded, becomes part of the eligibility assessment.

Exclusion criteria are equally important. Trials typically exclude patients with certain other eye conditions that could confound results, such as significant cataracts, glaucoma, diabetic retinopathy, or prior retinal surgeries. Medical conditions that might affect safety, such as uncontrolled high blood pressure, recent stroke, or pregnancy, may also disqualify potential participants. These exclusions protect patient safety and ensure that observed effects can be attributed to the treatment being studied rather than other factors.

⚠️ Important

Clinical trials use very specific diagnostic criteria to select participants. If you are considering participating in a trial for choroidal neovascularisation, you will need comprehensive diagnostic testing including OCT and possibly fluorescein angiography. The trial team will carefully review your medical history, current medications, and other health conditions. Meeting the entry criteria does not guarantee participation, as trials often have limited enrollment slots.

Baseline testing in clinical trials is extensive. Beyond standard imaging, participants may undergo specialized vision testing, including tests of reading speed, contrast sensitivity, and light sensitivity. These additional measurements help researchers understand the full impact of the condition and track subtle changes that standard visual acuity tests might miss. Some trials also assess quality of life through questionnaires, recognizing that vision affects daily activities, emotional well-being, and independence.

Follow-up diagnostic protocols in trials are strictly scheduled. Participants return for OCT scans, visual acuity measurements, and clinical examinations at predetermined intervals—often monthly or quarterly. This regular monitoring serves two purposes: it tracks treatment response and detects complications early. The rigorous follow-up in clinical trials often exceeds what patients receive in routine care, providing an additional safety net.

Some emerging trials investigate biomarkers that might predict treatment response or disease progression. These studies may collect blood samples to measure levels of vascular endothelial growth factor (VEGF) or other proteins involved in abnormal blood vessel growth. While these biomarkers are not yet part of standard diagnostic criteria, they represent an evolving area of research that may improve patient selection and personalized treatment in the future.^[6]

Prognosis and Survival Rate

Prognosis

The outlook for patients with choroidal neovascularisation depends heavily on how quickly the condition is detected and treated. When treatment begins promptly after symptoms appear—within hours or days—there is a much better chance of preserving vision. However, the natural history of untreated choroidal neovascularisation is concerning. Studies have shown that in untreated eyes followed for an average of nearly 12 years, macular atrophy developed in about 90 percent of cases. Most troublingly, visual acuity deteriorated to 20/200 or worse in more than 96 percent of untreated eyes by the 10-year mark.^[11]

Several factors influence the prognosis. The type and location of the neovascularisation matter: lesions directly under the center of vision (subfoveal) tend to cause more severe vision loss than those positioned away from the center. The underlying cause also affects outcomes. Choroidal neovascularisation related to age-related macular degeneration generally has a different trajectory than that caused by high myopia or inflammatory conditions. The presence of scar tissue or extensive bleeding at the time of diagnosis indicates more advanced disease and typically predicts poorer visual outcomes.

Even with modern treatment using anti-VEGF (vascular endothelial growth factor) injections, outcomes vary. Some patients respond dramatically, with vision improving and fluid resolving completely. Others experience stabilization, where vision stops declining but doesn’t improve significantly. A concerning subset of patients—up to one-fourth—shows little or no response to anti-VEGF treatment initially. Additionally, about one-third of those who initially respond well become resistant to the treatment over time with repeated administration.^[10]^[19]

The most important long-term determinant of visual outcome is the development of chorioretinal atrophy. Over time, the area where neovascularisation occurred may develop permanent thinning and loss of normal tissue. This atrophy process continues despite treatment and represents irreversible damage. Preventing or limiting this atrophy remains a major challenge in managing the condition.^[11]

Patients should understand that choroidal neovascularisation is a chronic condition requiring ongoing monitoring even after successful initial treatment. The abnormal blood vessels may become inactive with treatment, but the underlying conditions that triggered their growth often persist. Regular follow-up examinations are essential to detect recurrence early. Many patients require multiple treatments over months or years to maintain vision stability.

Survival Rate

Choroidal neovascularisation does not directly affect life expectancy or survival. It is an eye condition that threatens vision but not life itself. However, the impact on quality of life can be profound. The condition is a major cause of severe vision loss and blindness, particularly in adults of working age when caused by conditions like high myopia, and in elderly populations when related to age-related macular degeneration.^[2]^[11]

The term “survival” in the context of choroidal neovascularisation typically refers to preservation of useful vision rather than patient survival. Historical data from before effective treatments became available showed that vision survival was poor. Without intervention, patients faced progressive central vision loss that severely impacted their ability to read, drive, recognize faces, and perform detailed tasks. The introduction of anti-VEGF therapy revolutionized these outcomes, transforming what was once an inevitably blinding condition into one that can often be stabilized or improved.

Current data suggest that with appropriate treatment, many patients maintain reading vision and independence in daily activities. However, the effectiveness varies considerably among individuals. The best visual outcomes occur when treatment begins immediately after symptoms develop, before extensive damage occurs. This underscores the critical importance of recognizing symptoms early and seeking urgent evaluation.

#1 Clinical Trials Search in Europe